{"id":"prompt-aflibercept","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hemorrhage"},{"rate":null,"effect":"Eye pain"},{"rate":null,"effect":"Floaters"},{"rate":null,"effect":"Intraocular pressure elevation"},{"rate":null,"effect":"Arterial thromboembolic events"}]},"_chembl":{"chemblId":"CHEMBL1742982","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aflibercept functions as a fusion protein combining VEGF-binding domains from VEGF receptors 1 and 2 with the Fc portion of human immunoglobulin G. By sequestering circulating VEGF and PlGF, it prevents these growth factors from activating their cognate receptors on endothelial cells, thereby suppressing new blood vessel formation that supports tumor growth and pathological neovascularization in retinal diseases.","oneSentence":"Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit angiogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:21.234Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diabetic macular edema (DME)"},{"name":"Retinal vein occlusion (RVO)"},{"name":"Wet age-related macular degeneration (AMD)"},{"name":"Metastatic colorectal cancer (in combination with chemotherapy)"}]},"trialDetails":[{"nctId":"NCT02634333","phase":"PHASE3","title":"Anti-VEGF Treatment for Prevention of PDR/DME","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2016-01","conditions":"Diabetic Retinopathy, Diabetic Macular Edema","enrollment":399},{"nctId":"NCT02858076","phase":"PHASE2, PHASE3","title":"Anti-VEGF vs. Prompt Vitrectomy for VH From PDR","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2016-11","conditions":"Proliferative Diabetic Retinopathy, Vitreous Hemorrhage","enrollment":205},{"nctId":"NCT01909791","phase":"PHASE3","title":"Treatment for CI-DME in Eyes With Very Good VA Study","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2013-10","conditions":"Diabetic Macular Edema","enrollment":702}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":53,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["intravitreal anti-vascular endothelial growth factor","Eylea","intravitreal anti-VEGF"],"phase":"phase_3","status":"active","brandName":"Prompt aflibercept","genericName":"Prompt aflibercept","companyName":"Jaeb Center for Health Research","companyId":"jaeb-center-for-health-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit angiogenesis. Used for Diabetic macular edema (DME), Retinal vein occlusion (RVO), Wet age-related macular degeneration (AMD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}